Last reviewed · How we verify

NCT06847451

Assessment of Red Cell Distribution Width's Prognostic Ability in Septic Intensive Care Unit Patients

Completed Last updated 7 March 2025
What this trial tests

trial testing Prognostic biomarker as Red Cell Distribution Width in Sepsis in 60 participants. Completed in 14 September 2024.

Timeline
1 April 2024
Primary endpoint
1 September 2024
14 September 2024

Quick facts

Lead sponsorAin Shams University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date1 April 2024
Primary completion1 September 2024
Estimated completion14 September 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 18 to 70, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Various biomarkers are used for predicting outcome from sepsis and septic shock, but single value doesn't give a clear-cut picture. This prospective observational study aims to approach the prognostic value of Red Cell Distribution Width for morbidity and mortality of intensive care unit patients with sepsis. and this will be achieved by: * Assessment of prognostic value of red cell distribution width in septic intensive care unit patients for 28 days mortality * Comparison between red cell distribution width and other inflammatory markers as C-reactive protein and serum lactate as well as other scoring systems such as Sequential Organ Failure Assessment (SOFA) score, regarding their prognostic discriminative ability.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06847451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing